Climb Bio Inc Quick Ratio (CLYM) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Climb Bio Inc   (NASDAQ: CLYM)

Climb Bio Inc 's Quick Ratio

CLYM's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 25.98 below Climb Bio Inc average.

Within Major Pharmaceutical Preparations industry 14 other companies have achieved higher Quick Ratio than Climb Bio Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 129 to 139.

Explain Quick Ratio?
How much Cash & cash equivalents CLYM´s has?
What are CLYM´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/CLYM/financial-strength
https://api.csimarket.com/api/v1/companies/CLYM/fundamentals
https://api.csimarket.com/api/v1/companies/CLYM/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
CLYM Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 59.75 %
Y / Y Cash & cash equivalent Change 136.39 %
Quick Ratio MRQ 25.98
CLYM's Total Ranking # 139
Seq. Current Liabilities Change 33.23 %
Seq. Cash & cash equivalent Change 12.18 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 15
Healthcare Sector # 24
Overall Market # 139


Quick Ratio Statistics
High Average Low
59.65 27.48 8.89
(Jun 30 2024)   (Dec 31 2020)




Financial Statements
Climb Bio Inc 's Current Liabilities $ 8 Millions Visit CLYM's Balance sheet
Climb Bio Inc 's Cash & cash equivalent $ 205 Millions Visit CLYM's Balance sheet
Source of CLYM's Sales Visit CLYM's Sales by Geography


Cumulative Climb Bio Inc 's Quick Ratio

CLYM's Quick Ratio for the trailling 12 Months

CLYM Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months 		(Mar 31 2026)
12 Months 		(Dec 31 2025)
12 Months 		(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 18.27 %
Y / Y Cash & cash equivalent TTM Growth 42.47 %
Quick Ratio TTM 24.07
Total Ranking TTM # 3547
Seq. Current Liabilities TTM Growth 13.48 %
Seq. Cash & cash equivalent TTM Growth 24.66 %

Quick ratio ranking by company, industry and sector >> Back to CLYM Financial Strength Comparisons >> Go to Compare CLYM Quick Ratio to its Competitors

On the trailing twelve months basis CLYM Cash & cash equivalent more than doubled by 136.39 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Climb Bio Inc 's Quick Ratio to 24.07, above CLYM average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 421 other companies have achieved higher Quick Ratio than Climb Bio Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2245 to 3547.

Explain Quick Ratio?
How much Cash & cash equivalents CLYM´s has?
What are CLYM´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 422
Healthcare Sector # 858
Within the Market # 3547


trailing twelve months Quick Ratio Statistics
High Average Low
43.83 14.59 4.17
(Sep 30 2024)   (Mar 31 2026)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Q32 Bio Inc   56.05 $ 289.587  Millions$ 5.167  Millions
Rallybio Corporation  51.94 $ 90.693  Millions$ 1.746  Millions
Enliven Therapeutics Inc   45.41 $ 884.351  Millions$ 19.473  Millions
Bicara Therapeutics Inc   40.75 $ 442.346  Millions$ 10.856  Millions
Tango Therapeutics Inc   38.85 $ 977.503  Millions$ 25.164  Millions
Trevi Therapeutics Inc   38.05 $ 299.408  Millions$ 7.869  Millions
Boundless Bio Inc   33.60 $ 62.894  Millions$ 1.872  Millions
Minerva Neurosciences Inc   30.46 $ 76.945  Millions$ 2.526  Millions
Contineum Therapeutics Inc   30.45 $ 244.484  Millions$ 8.028  Millions
Latigo Biotherapeutics, Inc.  28.73 $ 401.241  Millions$ 13.964  Millions
Amylyx Pharmaceuticals Inc   26.44 $ 768.132  Millions$ 29.048  Millions
Climb Bio Inc   25.98 $ 205.423  Millions$ 7.906  Millions
Prothena Corporation Public Limited Company  23.73 $ 271.368  Millions$ 11.434  Millions
Innoviva Inc   22.67 $ 1,134.297  Millions$ 50.030  Millions
Kailera Therapeutics Inc   21.40 $ 901.454  Millions$ 42.116  Millions
Cryoport inc   20.47 $ 653.343  Millions$ 31.911  Millions
Roivant Sciences Ltd   20.30 $ 5,683.045  Millions$ 279.911  Millions
Disc Medicine Inc   19.87 $ 682.816  Millions$ 34.360  Millions
Mbx Biosciences Inc   19.14 $ 481.594  Millions$ 25.167  Millions
Telomir Pharmaceuticals Inc   19.07 $ 4.516  Millions$ 0.237  Millions
Onkure Therapeutics Inc   18.58 $ 163.305  Millions$ 8.789  Millions
Alto Neuroscience Inc   17.90 $ 319.344  Millions$ 17.836  Millions
Upstream Bio Inc   17.34 $ 207.365  Millions$ 11.960  Millions
Siga Technologies Inc  17.27 $ 116.380  Millions$ 6.738  Millions
Arrivent Biopharma inc   16.86 $ 393.691  Millions$ 23.357  Millions
Keros Therapeutics Inc   16.36 $ 259.464  Millions$ 15.858  Millions
Design Therapeutics Inc   16.36 $ 208.608  Millions$ 12.753  Millions
Whitehawk Therapeutics Inc   16.25 $ 169.672  Millions$ 10.441  Millions
Palvella Therapeutics Inc   15.85 $ 236.680  Millions$ 14.928  Millions
Avalo Therapeutics Inc   15.63 $ 392.966  Millions$ 25.135  Millions

Date modified: 2026-11-08T19:15:21+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.